[1]王梦林,王跃帮,杨苗苗,等. 宿迁地区健康成人血清肌酐参考区间的建立[J].当代医学,2022,28(16):75-77.
[2]李榕,王亮,钱豪英,等. 肌酐作为生物标志物在疾病诊断及药物评价方面的研究进展[J]. 药物评价研究,2021,44(9):2007-2012.
[3]贾蕊,薛丽,党永辉,等. 肌萎缩侧索硬化症患者的尿肌酐水平分析[J]. 西安交通大学学报(医学版),2020,41(6):821-825.
[4]万学红,卢雪峰. 诊断学[M].9版.北京:人民卫生出版社,2018:341-342.
[5]李雪文,王艺婷,何冰. 基于健康体检人群检验大数据建立血清尿素、肌酐参考区间[J]. 临床检验杂志,2021,39(10):795-796.
[6]王滋润,肖成伟,胡豇. 肾功能正常的中老年人群血清肌酐水平与骨密度相关性研究[J]. 中国骨质疏松杂志,2020,26(1):70-74.
[7]Lin YL,Chen SY,Lai YH,et al.Serumcreatinine to cystatin C ratio predicts skeletal muscle mass and strength in patients weith non-dialysis chronic kidney disease[J].Clin Nutr,2020,39(8):2435-2441.
[8]Tetsuka S,Morita M,Ikeguchi K,et al.Creatinine/Cystatin Cratio as a Surrogate Marker of Residual Muscle Mass in Amyotrophic Laterals Sclerosis[J]. Neurol Clin Neurosci,2013,1(1):32-37.
[9]林贤灿,吴建军,黄宏兴. 我国基层骨质疏松症防治的问题及策略[J].中国骨质疏松杂志,2022,28(11):1678-1682.
[10]Carreo JJ,Johansen KL,Lindholm B,et al.Screening for muscle wasting and dysfunction in patients with chronic kidney disease[J].Kidney Int,2016,90(1):53-66.
[11]杨迪,李少博,于浩泳. 血清肌酐与胱抑素C比值在糖代谢异常中的临床意义[J].上海医学,2021,44(10):739-744.
[12]K Ttgen A,Selvin E,Stevens LA,et al.Serum cystatin C in the United States:the Third National Health and Nutrition Examination Survey(NHANES Ⅲ)[J].Am J Kidney Dis,2008,51(3):385-394.
[13]Wang Q,Zheng D,Liu J,et al.Skeletal muscle mass to Visceral fat area ratio is an important determinant associated with type 2 diatetes and metabolic syndrome[J].Diabetes Metab Syndr obes,2019,12:1399-1407.
[14]刘彦儒,刘小林,龚婧如. 基于区域药学协作的糖尿病药物治疗管理模式实践效果[J].东南国防医药,2021,23(5):475-458.
[15]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中国实用内科杂志,2021,41(8):668-694.